- Press releases
- Events & Presentations
- Corporate Governance
- Shareholder & Stock Info
- Analyst Coverage
- Financial Reports
- Financial calendar
- Secured Rights issue 2018
- Secured Rights issue 2017
Board of directors
According to the articles of association Immunicum AB (publ)’s (the “Company”) board of directors shall consist of at least three (3) and at most eight (8) board members without deputies. The Company’s board of directors currently consists of seven (7) board members, including the chairman of the board of directors. All board members have been appointed until the end of next annual general meeting. Information regarding the Company’s board members, including year of birth, education and experiences, year of election to the board of board members, ongoing engagements and past engagements during the past five (5) years and shareholding in the Company (including indirect holdings and related persons’ holdings), can be found below.
Chairman since 2018
Shares: 17 560 MSc in International Business Administration Born: 1960
Experience: Michael Oredsson was until the end of 2017 CEO of publically-listed Bioinvent. Prior to that, Michael was CEO of Probi (2007-2013), Biosignal in Australia (2002-2007) and Nutripharma in Norway (1999-2001). During the eighties and nineties, he worked in senior positions in companies such as Pharmacia, M & M/Mars and Nestlé.
Ongoing engagements: Michael is currently CEO and board member of Biome Australia Ltd (Melbourne). CEO and Board member of NLSC – Northern Lights Southern Cross AB.
Independency: Michael Oredsson is independent in relation to the company, its senior executives and major shareholders.
Board member since 2016
Shares: 4000 M.D., Ph.D., Karolinska Institute, Stockholm Born: 1958
Experience: Charlotte Edenius has more than 20 years of experience from senior executives in pharmaceutical- and biotech companies, including experience from development of pharmaceuticals, regulatory issues and marketing. Charlotte has previously worked as Executive Vice President (R&D) at Medivir AB, Senior Vice President (R&D) at Orexo AB and as Vice President Research at Biolipox AB and various positions within clinical research and development at AstraZeneca.
Ongoing engagements: Chairman of the board of directors and CEO of Allmora Life Science AB. Board member of Kancera AB, SynAct Pharma AB and Gesynta Pharma AB.
Past engagements during the last five (5) years: Board member of Karolinska Institutet Innovations AB, Karolinska Development AB and Qlucore AB.
Independency: Charlotte Edenius is independent in relation to the company, its senior executives and major shareholders.
Board member since 2015
Physician and an associate Professor in Physiology at the Karolinska Institutet in Stockholm Born: 1960
Experience: Magnus Persson has 15 years’ experience as a partner in Venture Capital and has been partner in two Life Science Venture Capital companies, one based in Sweden but with global scope and one based in The Bay Area in California, USA. Magnus has extensive experience of financing within medicine, Life Science and biotechnology. He has been leading development teams in phase II and III-programs within the pharmaceutical industry. He has founded and lead both private and public biotech and medtech companies, as chairman of the board of directors and as board member in Europe and the USA. He has more than 90 years’ combined experience of board service within the Life Science industry and has been involved in tens of IPO’s.
Ongoing engagements: Chairman of the board of directors of SLS Invest AB, Attgeno AB, Addi Medical AB, Addi Optioner AB, Galecto Biotech AB, CANTARGIA AB and Perma Ventures AB. Board member of Karolinska Development AB, Gyros Protein Technologies Holding AB and Själbådan AB.
Past engagements during the last five (5) years: Chairman of the board of directors of Bio-works Technologies AB. Board member of Gyros Protein Technologies AB.
Independency: Magnus Persson is independent in relation to the company, its senior executives and major shareholders.
Board member since 2016
MD, University of Copenhagen and trained in Internal Medicine. Born: 1948
Experience: Steven Glazer is an experienced executive within health and biotech. He has extensive and broad experience from the therapeutic field, including hematology, oncology, hemophilia, HIV, diabetes, allergies and cardiovascular diseases from pharmaceutical and biotech companies in Europe and the USA. He has qualifications from successful planning and implementation of development strategies, regulatory strategies and business strategies, projects and study plans. Steven is Chief Medical Officer at Hansa Medical AB and has been working as Senior Vice President Development at BioInvent, Vice President Development at Zealand Pharma and Medical Director at Novo Nordisk.
Ongoing engagements: – Medical director of RhoVac AB. Chief Medical Officer of Idogen AB:
Past engagements during the last five (5) years: –
Independency: Steven Glazer is independent in relation to the company, its senior executives and major shareholders.
Board member since 2020
Doctorate in cell and molecular biology in medical science at Lund University Born: 1962
Helén Tuvesson is a Swedish citizen, born in 1962 and holds a doctor’s degree in cellular and molecular biology in medical science at Lund University. She has more than 25 years of experience from the pharmaceutical industry in various positions within Pharmacia and Active Biotech, including as Chief Scientific Officer at Active Biotech for 6 years. In this role she was responsible for the operational research activities and the company’s project portfolio in late stage clinical development in neurodegenerative diseases and cancer indications. Since 2017, Helén is the CEO of Active Biotech AB.
Independency: Helén Tuvesson is independent in relation to the company, its senior executives and major shareholders.
Board member since 2020
Shares: 15000 (through related) Bachelor's degree in Finance and Information Systems from New York University Born: 1974
Christine Lind is an American citizen, born in 1974. Christine Lind holds a bachelor’s degree in finance and information system from New York University, Stern School of Business, and an MBA-education in finance and management from Columbia Business School. Christine Lind has extensive experience from management roles in the global biotech industry (e.g. Vice President Business Development at LifeCell Corporation and Executive Vice President Business Development and subsequently CEO of Medivir AB) and as a strategic and financial advisor to biotech and pharmaceutical companies (at Merrill Lynch & Co). Christine Lind is currently a board member of Xspray Pharma and CEO and chairman of the board of directors of Lind Growth Strategy AB.
Independency: Christine Lind is independent in relation to the company, its senior executives and major shareholders.
Board member since 2020
MSc from Stockholm School of Economics and Business Administration Born: 1952
Sven Andreasson is a Swedish citizen, born in 1952 and resides in Washington DC, US. Sven holds a degree in business administration from Stockholm School of Economics and MBA-educations from IMEDE Lausanne, INSEAD Fontainebleau and Ashridge London. Sven has a wide experience from both biotech and pharmaceutical companies. He was CEO of Active Biotech in Lund 1999-2008, CEO of Beta- Cell in Belgium 2008-2012 and CEO of Isconova in Uppsala 2012-2013 where he initiated and completed a sale of the company in 2013 to the American company Novavax. Sven is currently working as Senior Vice President of Novavax with responsibility for business development. Sven has also held several senior management positions within Pharmacia in Sweden, Germany, Belgium and France. Previous experience from board assignments includes e.g. TiGenix (Belgium), Immunicum and Cantargia. Current board assignments consist of board member of Cellastra Inc (US) and Erytech SA (France) where he was chairman 2008-2013 and now a board member.
Independency: Sven Andreasson is independent in relation to the company, its senior executives and major shareholders.